The phosphatidylinositol-3-kinase (PI3K) pathway plays a crucial role in cell growth and survival and is activated in various cancers. Multiple components of the pathway are frequently targeted by ...

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression ...

PI3K inhibitors. Alpelisib (Piqray) and inavolisib (Itovebi) block a type of PI3K protein in cancer cells and can be used to treat certain types of breast cancer with a PIK3CA gene mutation.

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA ...

A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in ...

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

Torqur AG, an innovative clinical-stage biotechnology company dedicated to advancing treatments for oncology and dermatology, ...

Researchers from Tokyo University of Science uncover cellular and molecular mechanisms underlying the antidepressant-like effects of the delta opioid receptor agonists, paving the way for its ...

Phagocytosis is a fundamental mechanism used by the body to resist pathogens and restore physiological homeostasis. Herein, to identify small molecules with anti-inflammatory properties via ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

1 Primarily driven by an overactive PI3K pathway, early research suggests targeted therapy could hold promise for many patients. The study evaluates the safety and efficacy of topical gel ...